Literature DB >> 2820671

Malignant pseudomyxoma peritonei of colonic origin. Natural history and presentation of a curative approach to treatment.

P H Sugarbaker1, K Kern, E Lack.   

Abstract

Pseudomyxoma peritonei is an unusual malignancy arising from the goblet cells of the large bowel or appendix. Its characteristic clinical features are low histologic grade of malignancy and widespread dissemination throughout the abdominal cavity. In a clinical study of 14 patients, the most common initial symptoms were abdominal distention or right lower quadrant pain suggestive of appendicitis. All patients underwent radical procedures in an attempt to surgically remove all gross disease from the abdomen. Six patients had small-bowel obstruction and five of these had bowel function restored. All of eight patients had relief from bulky intra-abdominal tumors. Six cycles of intraperitoneal 5-FU and three doses of mitomycin C were used following cytoreductive surgery in seven patients. Five of these seven patients are disease free following staging by celiotomy with two- to four-year follow-up. This new treatment strategy, designed to cure some patients with pseudomyxoma peritonei, has given favorable results in a disease that previously had a uniformly lethal outcome.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2820671     DOI: 10.1007/BF02554625

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  39 in total

1.  Pseudomyxoma peritonei.

Authors:  Katharine E Bevan; Faheez Mohamed; Brendan J Moran
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

2.  Are there curative options to peritoneal carcinomatosis?

Authors:  Paul H Sugarbaker
Journal:  Ann Surg       Date:  2005-11       Impact factor: 12.969

Review 3.  Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.

Authors:  Manuel J Koppe; Otto C Boerman; Wim J G Oyen; Robert P Bleichrodt
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

4.  Classification of encapsulating peritoneal sclerosis is important, but must encapsulate the entire spectrum of the disease.

Authors:  Christopher J E Watson; Andrew J Butler; J Andrew Bradley
Journal:  Perit Dial Int       Date:  2013 Sep-Oct       Impact factor: 1.756

Review 5.  Surgical treatment of peritoneal carcinomatosis: current treatment modalities.

Authors:  Yakup Kulu; Beat Müller-Stich; Markus W Büchler; Alexis Ulrich
Journal:  Langenbecks Arch Surg       Date:  2013-11-19       Impact factor: 3.445

6.  Management of Peritoneal Carcinomatosis With Cytoreductive Surgery Combined With Intraperitoneal Chemohyperthermia at a Novel Italian Center.

Authors:  Pinuccia Faviana; Laura Boldrini; Barbara Musco; Mauro Ferrari; Alfonso Greco; Lorenzo Fornaro; Gianluca Masi; Francesco Forfori; Sergio Ricci; Augusto Brogi; Fulvio Basolo; Alfredo Falcone; Angelo Gadducci; Piero Vincenzo Lippolis
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

7.  Primary Appendicular Malignancy Presenting as Abdominal Wall Abscess with Secondary Tuberculosis Infection: an Interesting Case Report.

Authors:  Ritim Ravi Patel; Vipul Versi Nandu
Journal:  Indian J Surg Oncol       Date:  2018-08-07

8.  Pseudomyxoma extraperitonei: a rare presentation of a rare tumour.

Authors:  Carmina Diaz-Zorrilla; Antonio Ramos-De la Medina; Peter Grube-Pagola; Alfredo Ramirez-Gutierrez de Velasco
Journal:  BMJ Case Rep       Date:  2013-02-04

9.  The natural history of surgically treated primary adenocarcinoma of the appendix.

Authors:  S S Nitecki; B G Wolff; R Schlinkert; M G Sarr
Journal:  Ann Surg       Date:  1994-01       Impact factor: 12.969

10.  Glycomic Profiling Highlights Increased Fucosylation in Pseudomyxoma Peritonei.

Authors:  Lilli Saarinen; Pirjo Nummela; Hannele Leinonen; Annamari Heiskanen; Alexandra Thiel; Caj Haglund; Anna Lepistö; Tero Satomaa; Sampsa Hautaniemi; Ari Ristimäki
Journal:  Mol Cell Proteomics       Date:  2018-08-02       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.